Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities	RET-altered Non Small Cell Lung Cancer; RET-altered Solid Tumors	Recruiting	Phase 1 / Phase 2	2026-08-19		NCT04683250

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Taiho Pharmaceutical Co., Ltd.	8

29 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Aichi Cancer Center	Aichi	Japan	1
Cabrini Hospital	Malvern	Australia	2
Chao Family Comprehensive Cancer Center	Orange	United States	1
GenesisCare North Shore	Saint Leonards	Australia	2
Henry Ford Hospital	Detroit	United States	326
Kanagawa Cancer Center	Kanagawa	Japan	5
Kansai Medical University Hospital	Hirakata-shi	Japan	4
Kindai University Hospital	Osaka	Japan	6
Kurashiki Central Hospital	Okayama	Japan	3
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health	New York	United States	6
Linear Clinical Research	Nedlands	Australia	2
Massachusetts General Hospital	Boston	United States	1015
Memorial Sloan Kettering Cancer Center	New York	United States	1000
National Cancer Center Hospital	Chuo-ku	Japan	67
National Cancer Center Hospital East	Kashiwa-shi	Japan	11
National Hospital Organization Kyushu Cancer Center	Fukuoka	Japan	6
Okayama University Hospital	Okayama	Japan	5
Osaka International Cancer Institute	Osaka	Japan	10
Samsung Medical Center	Seoul	South Korea	170
Seoul National University Bundang Hospital	Seongnam	South Korea	42
Seoul National University Hospital	Seoul	South Korea	183
Severance Hospital	Seoul	South Korea	62
Shizuoka Cancer Center	Shizuoka	Japan	1
Stanford Cancer Center	Stanford	United States	1
START Midwest - Cancer & Hematology Centers of Western Michigan	Grand Rapids	United States	1

Clinical trials